Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | SL-279252 |
Synonyms | |
Therapy Description |
SL-279252 is a chimeric fusion protein that consists of the extracellular domains of PD-1 (PDCD1) and OX40L (TNFSF4) linked by an Fc domain, which may result in both immune checkpoint inhibition and TNF receptor activation, leading to increased antitumor immune response (PMID: 30563566). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
SL-279252 | SL 279252|SL279252|PD1-Fc-OX40L | Immune Checkpoint Inhibitor 149 | SL-279252 is a chimeric fusion protein that consists of the extracellular domains of PD-1 (PDCD1) and OX40L (TNFSF4) linked by an Fc domain, which may result in both immune checkpoint inhibition and TNF receptor activation, leading to increased antitumor immune response (PMID: 30563566). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03894618 | Phase I | SL-279252 | SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas | Completed | USA | ESP | CAN | BEL | 0 |